{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T03:18:11Z","timestamp":1752549491183,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,8,11]],"date-time":"2018-08-11T00:00:00Z","timestamp":1533945600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"crossref","award":["HHSN275201000003I"],"award-info":[{"award-number":["HHSN275201000003I"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Pediatric Trials Network","award":["NICHD-2012-PAN01"],"award-info":[{"award-number":["NICHD-2012-PAN01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40272-018-0305-1","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T21:23:51Z","timestamp":1533936231000},"page":"483-495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents"],"prefix":"10.1007","volume":"20","author":[{"name":"On behalf of the Best Pharmaceuticals for Children Act\u2013Pediatric Trials Network","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Shakhnovich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Brian Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey T.","family":"Guptill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura P.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David N.","family":"Collier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huali","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad E.","family":"Livingston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory L.","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Cohen-Wolkowiez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,11]]},"reference":[{"issue":"130","key":"305_CR1","first-page":"23","volume":"2002\u20132010","author":"G Chai","year":"2012","unstructured":"Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D. Trends of outpatient prescription drug utilization in US. Children. 2012;2002\u20132010(130):23\u201331.","journal-title":"Children"},{"key":"305_CR2","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1001\/jama.2014.732","volume":"311","author":"CL Ogden","year":"2014","unstructured":"Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011\u20132012. JAMA. 2014;311:806\u201314.","journal-title":"JAMA"},{"key":"305_CR3","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.3109\/17477166.2010.491118","volume":"6","author":"C Koebnick","year":"2011","unstructured":"Koebnick C, Getahun D, Smith N, Porter AH, Der-Sarkissian JK, Jacobsen SJ. Extreme childhood obesity is associated with increased risk for gastroesophageal reflux disease in a large population-based study. Int J Pediatr Obes. 2011;6:e267\u20138.","journal-title":"Int J Pediatr Obes."},{"key":"305_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2165\/00128072-200305010-00003","volume":"5","author":"TE Gibbons","year":"2003","unstructured":"Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs. 2003;5:25\u201340.","journal-title":"Paediatr Drugs"},{"key":"305_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00003088-200039030-00004","volume":"39","author":"G Cheymol","year":"2000","unstructured":"Cheymol G. Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet. 2000;39:215\u201331.","journal-title":"Clin Pharmacokinet"},{"key":"305_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","volume":"51","author":"MJE Brill","year":"2012","unstructured":"Brill MJE, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug meatabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51:277\u2013304.","journal-title":"Clin Pharmacokinet"},{"key":"305_CR7","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1001\/jamapediatrics.2015.132","volume":"169","author":"MW Harskamp-van Ginkel","year":"2015","unstructured":"Harskamp-van Ginkel MW, Hill KD, Becker KC, Testoni D, Cohen-Wolkowiez M, Gonzalez D, et al. Drug dosing and pharmacokinetics in children with obesity: a systematic review. JAMA Pediatr. 2015;169:678\u201385.","journal-title":"JAMA Pediatr."},{"key":"305_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-pharmtox-010814-124354","volume":"55","author":"CA Knibbe","year":"2015","unstructured":"Knibbe CA, Brill MJ, van Rongen A, Diepstraten J, van der Graaf PH, Danhof M. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol. 2015;55:149\u201367.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"102\u20138","key":"305_CR9","first-page":"e1","volume":"193","author":"V Shakhnovich","year":"2018","unstructured":"Shakhnovich V, Smith PB, Guptill JT, James LP, Collier DN, Wu H, et al. Obese children require lower doses of pantoprazole than nonobese peers to achieve equal systemic drug exposures. J Pediatr. 2018;193(102\u20138):e1.","journal-title":"J Pediatr"},{"key":"305_CR10","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.clinthera.2015.08.006","volume":"37","author":"S Rowe","year":"2015","unstructured":"Rowe S, Siegel D, Benjamin DK Jr. Gaps in drug dosing for obese children: a systematic review of commonly prescribed emergency care medications. Clin Ther. 2015;37:1924\u201332.","journal-title":"Clin Ther"},{"key":"305_CR11","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/j.clinthera.2015.05.495","volume":"37","author":"JG Kendrick","year":"2015","unstructured":"Kendrick JG, Carr RR, Ensom MH. Pediatric obesity: pharmacokinetics and implications for drug dosing. Clin Ther. 2015;37:1897\u2013923.","journal-title":"Clin Ther"},{"key":"305_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/cts.12475","volume":"10","author":"E Dubcenco","year":"2017","unstructured":"Dubcenco E, Beers-Block PM, Kim L, Schotland P, Levine JG, McCloskey CA, et al. A proton pump inhibitor in the reformulation setting: bioequivalence and potential implications for long-term safety. Clin Transl Sci. 2017;10:387\u201394.","journal-title":"Clin Transl Sci."},{"key":"305_CR13","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44:1051\u201365.","journal-title":"Clin Pharmacokinet"},{"key":"305_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","volume":"101","author":"RJ Keizer","year":"2011","unstructured":"Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD. Pira\u00f1a and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101:72\u20139.","journal-title":"Comput Methods Programs Biomed"},{"key":"305_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85\u201394.","journal-title":"Comput Methods Programs Biomed"},{"key":"305_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO. Xpose\u2014an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51\u201364.","journal-title":"Comput Methods Programs Biomed"},{"key":"305_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","volume":"34","author":"RM Savic","year":"2007","unstructured":"Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34:711\u201326.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"305_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00007691-200402000-00006","volume":"26","author":"A Rousseau","year":"2004","unstructured":"Rousseau A, L\u00e9ger F, Le Meur Y, Saint-Marcoux F, Paintaud G, Buchler M, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit. 2004;26:23\u201330.","journal-title":"Ther Drug Monit"},{"key":"305_CR19","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1128\/AAC.02942-15","volume":"60","author":"A Desai","year":"2016","unstructured":"Desai A, Schmitt-Hoffmann AH, Mujais S, Townsend R. Population pharmacokinetics of isavuconazole in subjects with mild or moderate hepatic impairment. Antimicrob Agents Chemother. 2016;60:3025\u201331.","journal-title":"Antimicrob Agents Chemother"},{"key":"305_CR20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/bdd.1863","volume":"34","author":"SA Wart Van","year":"2013","unstructured":"Van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE. Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. Biopharm Drug Dispos. 2013;34:527\u201339.","journal-title":"Biopharm Drug Dispos"},{"key":"305_CR21","doi-asserted-by":"publisher","first-page":"e00131","DOI":"10.1002\/prp2.131","volume":"3","author":"RJ Keizer","year":"2015","unstructured":"Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JH, et al. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacol Res Perspect. 2015;3:e00131.","journal-title":"Pharmacol Res Perspect."},{"key":"305_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"305_CR23","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/jps.23574","volume":"102","author":"N Holford","year":"2013","unstructured":"Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102:2941\u201352.","journal-title":"J Pharm Sci"},{"key":"305_CR24","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1365-2125.1981.tb01163.x","volume":"11","author":"TH Hallynck","year":"1981","unstructured":"Hallynck TH, Soep HH, Thomis JA, Boelaert J, Daneels R, Dettli L. Should clearance be normalised to body surface or to lean body mass? Br J Clin Pharmacol. 1981;11:523\u20136.","journal-title":"Br J Clin Pharmacol"},{"key":"305_CR25","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/bja\/aer057","volume":"106","author":"AM Peters","year":"2011","unstructured":"Peters AM, Snelling HL, Glass DM, Bird NJ. Estimation of lean body mass in children. Br J Anaesth. 2011;106:719\u201323.","journal-title":"Br J Anaesth"},{"key":"305_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2253-14-77","volume":"14","author":"K Allegaert","year":"2014","unstructured":"Allegaert K, Olkkola KT, Owens KH, Van de Velde M, de Maat MM, Anderson BJ. Covariates of intravenous paracetamol pharmacokinetics in adults. BMC Anesthesiol. 2014;14:77.","journal-title":"BMC Anesthesiol."},{"key":"305_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2133\/dmpk.24.25","volume":"24","author":"BJ Anderson","year":"2009","unstructured":"Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24:25\u201336.","journal-title":"Drug Metab Pharmacokinet"},{"key":"305_CR28","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s40262-015-0277-z","volume":"54","author":"HS Al-Sallami","year":"2015","unstructured":"Al-Sallami HS, Goulding A, Grant A, Taylor R, Holford N, Duffull SB. Prediction of fat-free mass in children. Clin Pharmacokinet. 2015;54:1169\u201378.","journal-title":"Clin Pharmacokinet"},{"key":"305_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2133\/dmpk.24.145","volume":"24","author":"B Habtemariam","year":"2009","unstructured":"Habtemariam B, Sallas W, Sunkara G, Kern S, Jarugula V, Pillai G. Population pharmacokinetics of valsartan in pediatrics. Drug Metab Pharmacokinet. 2009;24:145\u201352.","journal-title":"Drug Metab Pharmacokinet"},{"key":"305_CR30","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s00228-015-1948-2","volume":"71","author":"LI Cortinez","year":"2015","unstructured":"Cortinez LI, Anderson BJ, Holford NH, Puga V, de la Fuente N, Auad H, et al. Dexmedetomidine pharmacokinetics in the obese. Eur J Clin Pharmacol. 2015;71:1501\u20138.","journal-title":"Eur J Clin Pharmacol"},{"key":"305_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/0091270010390040","volume":"52","author":"DD Wang","year":"2012","unstructured":"Wang DD, Zhang S. Standardized visual predictive check versus visual predictive check for model evaluation. J Clin Pharmacol. 2012;52:39\u201354.","journal-title":"J Clin Pharmacol"},{"key":"305_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/bcp.12619","volume":"80","author":"S Cohen","year":"2015","unstructured":"Cohen S, Bueno de Mesquita M, Mimouni FB. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10\u00a0years literature review. Br J Clin Pharmacol. 2015;80:200\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"305_CR33","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1177\/0091270010377501","volume":"51","author":"RM Ward","year":"2011","unstructured":"Ward RM, Kearns GL, Tammara B, Bishop P, O\u2019Gorman MA, James LP, et al. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16\u00a0years with gastroesophageal reflux disease. J Clin Pharmacol. 2011;51:876\u201387.","journal-title":"J Clin Pharmacol"},{"key":"305_CR34","unstructured":"PROTONIX\u00ae (pantoprazole sodium) delayed-release tablets and PROTONIX\u00ae (pantoprazole sodium) for delayed-release oral suspension (U.S. package insert). Collegeville, Pa: Wyeth; 2009. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022020s011-020987s049lbl.pdf\n                    \n                  . Accessed 8 Aug 2018."},{"key":"305_CR35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.5639\/gabij.2013.0202.025","volume":"2","author":"MR Sampson","year":"2013","unstructured":"Sampson MR, Cohen-Wolkowiez M, Benjamin D Jr, Capparelli E, Watt K. Pharmacokinetics of antimicrobials in obese children. GaBi J. 2013;2:76\u201381.","journal-title":"GaBi J."},{"key":"305_CR36","unstructured":"Clinical Pharmacology and Biopharmaceutics Review(s). \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/20987_Protonix_biopharmr_P2.pdf\n                    \n                  . Accessed 21 Sep 2017."},{"key":"305_CR37","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1177\/0091270008321811","volume":"48","author":"GL Kearns","year":"2008","unstructured":"Kearns GL, Blumer J, Schexnayder S, James LP, Adcock KG, Reed MD, et al. Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents. J Clin Pharmacol. 2008;48:1356\u201365.","journal-title":"J Clin Pharmacol"},{"key":"305_CR38","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1177\/0091270010366146","volume":"51","author":"W Knebel","year":"2011","unstructured":"Knebel W, Tammara B, Udata C, Comer G, Gastonguay MR, Meng X. Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years. J Clin Pharmacol. 2011;51:333\u201345.","journal-title":"J Clin Pharmacol"},{"key":"305_CR39","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0009-9236(97)90081-3","volume":"62","author":"M Tanaka","year":"1997","unstructured":"Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, et al. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4\u2032-hydroxylation phenotype and genotype. Clin Pharmacol Ther. 1997;62:619\u201328.","journal-title":"Clin Pharmacol Ther"},{"key":"305_CR40","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/ajg.2009.632","volume":"105","author":"WY Chen","year":"2010","unstructured":"Chen WY, Chang WL, Tsai YC, Cheng HC, Lu CC, Sheu BS. Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. Am J Gastroenterol. 2010;105:1046\u201352.","journal-title":"Am J Gastroenterol"},{"key":"305_CR41","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/\u2026\/20988_Protonix_biopharmr.pdf\n                    \n                  . Accessed 21 Sep 2017."},{"key":"305_CR42","unstructured":"World Health Organization. Global strategy on diet, physical activity and health: childhood overweight and obesity. Available at: \n                    http:\/\/www.who.int\/dietphysicalactivity\/childhood\n                    \n                  . Accessed 16 Aug 2017."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-018-0305-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-018-0305-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-018-0305-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T19:11:36Z","timestamp":1565464296000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-018-0305-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,11]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1007\/s40272-018-0305-1","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"type":"print","value":"1174-5878"},{"type":"electronic","value":"1179-2019"}],"subject":[],"published":{"date-parts":[[2018,8,11]]},"assertion":[{"value":"11 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All phases of this study were supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (HHSN275201000003I), Pediatric Trials Network (NICHD-2012-PAN01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"VS. receives research support from the NASPGHAN Foundation for the investigation of PPIs in children. As an associate editor, V.S. receives honoraria from the journal Clinical and Translational Science. M.C.W. receives support for research from the National Institutes of Health (1R01-HD076676-01A1), the National Institute of Allergy and Infectious Disease (HHSN272201500006I and HHSN272201300017I), the National Institute of Child Health and Human Development (HHSN275201000003I), and the Biomedical Advanced Research and Development Authority (HHSO100201300009C). The remaining authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}